Acceleron to Participate in Two Healthcare Investor Conferences in May
02 Mayo 2018 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced that
senior management will participate in two upcoming healthcare
investor conferences in May.
Conference Details:
Event: Deutsche Bank 43rd Annual Health Care ConferenceDate:
Tuesday, May 8, 2018Location: Boston, MA
Event: UBS Global Healthcare ConferenceDate/Time: Tuesday, May
22, 2018 at 1:30 p.m. EDTLocation: New York, NY
A live audio webcast for the UBS conference will be
available on the Investors/Media page of the Company's website
at www.acceleronpharma.com. A replay of the webcast will be
available approximately two hours after the event on the Acceleron
website.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company’s leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body’s ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with a Phase 2 trial of sotatercept planned in pulmonary
arterial hypertension.
For more information, please
visit www.acceleronpharma.com/. Follow Acceleron on Social
Media: @AcceleronPharma and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180502005192/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024